Robust real-world data on the effectiveness of biologic therapies in children with severe asthma remain limited, particularly ...

Add Yahoo as a preferred source to see more of our stories on Google. Pulmonologist doctor showing off virtual screen of lung medical issue. Healthcare medical technology concept. Approximately 25 ...

Nonclinical factors are more likely to drive discontinuation of biologic therapy for patients with severe asthma.

People with severe asthma may not respond to the usual treatment. Researchers have examined what drives the inflammatory response in severe asthmatics at a molecular level and their findings may lead ...

In December 2021, the US Food and Drug Administration (FDA) approved Tezspire (tezepelumab-ekko; Amgen, Inc and AstraZeneca AB), a thymic stromal lymphopoietin (TSLP) blocker, for the add-on ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Patients who received biologic treatment for asthma did ...

Exdensur (depemokimab) in two indications, including: As an add-on maintenance treatment for severe asthma with type 2 inflammation, characterized by blood eosinophil count in adults and adolescents ...

Please provide your email address to receive an email when new articles are posted on . Mucus scores included 6 for the nonbiologic group and 3 for the biologic group. Mucus scores also included 5 for ...

Researchers are tackling neutrophilic asthma, successfully developing one of the first mouse models of the condition. A better understanding of inflammation and lung immunity over the past two decades ...

Asthma isn’t always a quick and easy diagnosis in children. According to a 2014 task force assembled by the American Thoracic Society and the European Respiratory Society, pediatric severe asthma can ...

Researchers are evaluating whether biologic therapies for severe asthma reduce the risk for osteoarthritis progression in ...